Apparent Mineralocorticoid Excess — designated AME, OMIM #218030, an autosomal recessive disorder of cortisol metabolism caused by biallelic loss-of-function mutations in HSD11B2 encoding 11β-hydroxysteroid dehydrogenase type 2 (11β-HSD2), the NAD+-dependent enzyme expressed in the epithelial cells of the aldosterone-sensitive distal nephron (connecting tubule, cortical collecting duct principal cells), colonocytes, placenta, and salivary gland epithelium that normally catalyzes the intracellular conversion of cortisol (the primary circulating glucocorticoid — biologically active, capable of binding mineralocorticoid receptor [MR] with affinity equivalent to aldosterone since the MR ligand-binding domain cannot structurally distinguish cortisol from aldosterone) to the inactive cortisone (which cannot bind MR because it lacks the 11β-hydroxyl group required for receptor docking) — thereby protecting mineralocorticoid-sensitive tissues from inappropriate glucocorticoid-mediated mineralocorticoid receptor activation despite plasma cortisol concentrations that are approximately 100-1000 times higher than plasma aldosterone concentrations in healthy individuals, with the 11β-HSD2 enzymatic barrier functioning as the critical pre-receptor intracellular "cortisol exclusion" mechanism that ensures MR occupancy in aldosterone-sensitive tissues reflects aldosterone signaling rather than glucocorticoid excess; where HSD11B2 biallelic loss-of-function mutations (missense variants concentrated at residues involved in NAD+ cofactor binding or catalytic site geometry — notably R213C and R337C in Western populations — plus nonsense, frameshift, splice-site, and gene deletion variants) eliminate or severely reduce 11β-HSD2 enzymatic activity in mineralocorticoid-sensitive tissues, allowing cortisol to accumulate intracellularly and occupy the mineralocorticoid receptor in the aldosterone-sensitive distal nephron exactly as aldosterone would, activating the full aldosterone-response gene network — SCNN1A, SCNN1B, SCNN1G (upregulating apical ENaC subunit expression), FXYD4, SGK1 (serum and glucocorticoid-regulated kinase 1, the primary aldosterone-induced kinase that phosphorylates NEDD4-2 to prevent ENaC internalization and amplify ENaC surface density), and the Na+/K+-ATPase subunits (increasing basolateral sodium extrusion capacity) — producing excessive transepithelial sodium reabsorption in the distal nephron equivalent to primary hyperaldosteronism but driven by cortisol rather than aldosterone, with the consequent clinical phenotype of severe early-onset hypertension (often presenting in childhood or adolescence with blood pressure exceeding 180/110 mmHg — some of the most severe hypertension in pediatric medicine), hypokalemia from cortisol-driven lumen electronegativity promoting distal potassium secretion through ROMK, metabolic alkalosis from concurrent H+ secretion, markedly suppressed plasma renin activity and paradoxically suppressed plasma aldosterone (from volume expansion-mediated renin suppression and renin-driven angiotensin II being the primary aldosterone secretagogue — distinguishing AME from primary hyperaldosteronism where aldosterone is elevated, and producing the same suppressed-aldosterone-suppressed-renin biochemical pattern as Liddle syndrome but through an entirely different molecular mechanism), and critically a urinary steroid profile showing markedly elevated cortisol-to-cortisone ratio (measured as the THF+alloTHF/THE ratio on 24-hour urine steroid profiling by gas chromatography-mass spectrometry — the tetrahydro metabolites of cortisol and cortisone, respectively) that is the diagnostic hallmark of 11β-HSD2 deficiency, distinguishing AME biochemically from Liddle syndrome (where the cortisol-to-cortisone ratio is normal); where the clinical response pattern further distinguishes AME from Liddle syndrome — AME responds to spironolactone (which blocks the mineralocorticoid receptor occupied by cortisol in 11β-HSD2-deficient tissues, unlike in Liddle syndrome where constitutive ENaC activity is downstream of MR and spironolactone has no effect) and to dexamethasone (which suppresses ACTH-driven adrenal cortisol production, reducing the cortisol substrate available to overwhelm the absent 11β-HSD2 enzymatic barrier and thereby reducing MR activation by cortisol — a treatment approach that also helps in AME but has no role in Liddle syndrome); and where acquired AME from exogenous glycyrrhizin exposure deserves mention — glycyrrhizic acid and its active metabolite glycyrrhetinic acid (the active compound in licorice root, Glycyrrhiza glabra, and licorice-containing products including herbal preparations, licorice confectionery, anise-flavored tobacco products, and certain traditional medicines) are potent pharmacological inhibitors of 11β-HSD2 that produce a fully reversible biochemical and clinical AME phenotype identical to genetic HSD11B2 deficiency during exposure, resolving completely with licorice avoidance — making dietary history and licorice exposure documentation an essential component of AME evaluation in every newly diagnosed case — making AME the archetypal acquired-or-genetic mineralocorticoid excess disorder caused by failure of cortisol exclusion from mineralocorticoid-sensitive tissues, affecting fewer than 1 in 1,000,000 individuals with genetic HSD11B2 deficiency.
Apparent mineralocorticoid excess technology platforms — encompassing the endocrine hypertension medicine platforms where the young patient with severe hypertension, hypokalemia, and suppressed renin and suppressed aldosterone triggers the differential diagnostic workup between AME (elevated urine cortisol-to-cortisone ratio), Liddle syndrome (normal urine cortisol-to-cortisone ratio, SCNN1B/SCNN1G mutation), and Gordon syndrome (hyperkalemia rather than hypokalemia — excluding both), the clinical biochemistry laboratory platforms performing 24-hour urine steroid profiling by GC-MS measuring tetrahydrocortisol (THF), allotetrahydrocortisol (alloTHF), and tetrahydrocortisone (THE) to calculate the THF+alloTHF/THE ratio diagnostic of 11β-HSD2 deficiency, the plasma free cortisol and cortisone ratio platforms (LC-MS/MS measurement of plasma cortisol and cortisone — a more technically accessible screening test than 24-hour urine GC-MS when the latter is not immediately available), the molecular genetics platforms sequencing HSD11B2 for biallelic loss-of-function mutations confirming genetic AME, the ambulatory blood pressure monitoring platforms tracking hypertension severity and therapeutic response to spironolactone and dexamethasone, the serum potassium and metabolic panel platforms monitoring hypokalemia correction during mineralocorticoid receptor blockade, the adrenal imaging platforms (CT and MRI) excluding bilateral adrenal hyperplasia or aldosterone-producing adenoma when the initial biochemical evaluation has not yet confirmed the 11β-HSD2 mechanism, the cardiac surveillance platforms coordinating echocardiography for left ventricular hypertrophy assessment given the severity of the hypertension in AME, the ECG monitoring platforms for QTc surveillance during severe hypokalemia, the 24-hour urine cortisol platforms confirming that dexamethasone is adequately suppressing ACTH-driven cortisol production, and the dietary counseling platforms documenting licorice avoidance adherence for genetic AME patients and monitoring for relapse from inadvertent glycyrrhizin exposure in foods, tobacco products, or herbal supplements — must maintain the availability and performance standards required by the diagnostic biochemical complexity of cortisol-to-cortisone ratio measurement, the severity of early-onset hypertension management, and the long-term surveillance obligations of a condition where treatment adherence is monitored by biochemical markers rather than symptom assessment. This guide explains why AME tech platforms need dedicated monitoring, what components to monitor, and how to build a monitoring strategy matched to the steroid profiling precision, blood pressure and electrolyte surveillance intensity, dual pharmacotherapy management, and licorice avoidance counseling obligations of modern AME care.
Why Apparent Mineralocorticoid Excess Tech Platforms Require Specialized Monitoring Attention
AME management is defined by several uniquely complex cortisol-excess mineralocorticoid activation challenges: the biochemical misdiagnosis urgency — AME is misdiagnosed as essential hypertension or Liddle syndrome or primary hyperaldosteronism in the majority of cases because the suppressed-renin-suppressed-aldosterone profile is shared with Liddle syndrome, and only the 24-hour urine steroid profile (elevated THF+alloTHF/THE ratio) or plasma cortisol-to-cortisone ratio differentiates AME from Liddle syndrome biochemically, requiring the clinical biochemistry platforms performing GC-MS urine steroid profiling to be reliably available during the diagnostic evaluation; the acquired AME licorice exposure missed-diagnosis problem — because glycyrrhizin-induced acquired AME is common relative to the extremely rare genetic form, the initial evaluation of every apparent AME case must document licorice exposure history, and the management includes licorice and tobacco product avoidance that must be documented and reinforced at every contact, requiring platforms tracking dietary and exposure history to remain available for the treating clinician; the treatment mechanism distinction from Liddle syndrome — spironolactone is effective in AME (by blocking MR occupied by cortisol) and ineffective in Liddle syndrome (ENaC activity is post-MR and not suppressed by MR antagonism), while amiloride is effective in Liddle syndrome and less specifically effective in AME, so the platform providing the urine cortisol-to-cortisone ratio result that distinguishes AME from Liddle syndrome directly determines which medication class is initiated; and the dexamethasone cortisol suppression monitoring obligation — because dexamethasone therapy in AME works by suppressing ACTH and thereby reducing adrenal cortisol production to reduce the substrate overwhelming 11β-HSD2, the platforms measuring 24-hour urine cortisol and plasma cortisol during dexamethasone titration must remain available to confirm adequate ACTH suppression without causing glucocorticoid excess or adrenal suppression.
24-hour urine steroid profiling platforms are the primary biochemical diagnosis tool for AME. Gas chromatography-mass spectrometry measurement of 24-hour urine tetrahydro-cortisol metabolites (THF, alloTHF) and cortisone metabolite (THE) with calculation of the THF+alloTHF/THE ratio (markedly elevated [>10, often >30, in AME versus normal ratio of 1–2] from 11β-HSD2 inability to convert cortisol to cortisone in mineralocorticoid-sensitive tissues) is the diagnostic hallmark of AME, distinguishing from Liddle syndrome where this ratio is normal. Monitor 24-hour urine GC-MS steroid profiling platforms at 1-minute intervals during laboratory hours.
HSD11B2 molecular sequencing platforms provide genetic confirmation and distinguish genetic from acquired AME. Biallelic HSD11B2 loss-of-function variant identification confirms genetic AME, enabling family cascade testing (carrier parent identification and sibling risk assessment) and definitively excluding acquired glycyrrhizin-induced AME where no HSD11B2 mutation is present. Monitor HSD11B2 sequencing platforms at 1-minute intervals during laboratory hours.
Ambulatory blood pressure monitoring platforms track the severe hypertension severity and treatment response. Twenty-four-hour ABPM providing daytime, nighttime, and 24-hour mean blood pressure before and during spironolactone and dexamethasone therapy quantifies the therapeutic response — blood pressure normalization being the primary endpoint of both MR antagonism and cortisol suppression therapies. Monitor ABPM platforms at 1-minute intervals during clinical hours.
Dexamethasone cortisol suppression monitoring platforms confirm therapeutic glucocorticoid adequacy. 24-hour urine free cortisol and morning plasma cortisol during dexamethasone titration confirm adequate ACTH suppression without causing iatrogenic glucocorticoid excess — the monitoring challenge unique to dexamethasone therapy in AME. Monitor cortisol suppression platforms at 1-minute intervals during laboratory hours.
Dietary and licorice avoidance counseling platforms track the primary modifiable acquired trigger. Licorice avoidance (including herbal preparations, confectionery, anise-flavored tobacco, and pharmaceutical excipients) and tobacco avoidance (tobacco also contains glycyrrhizin-related compounds with 11β-HSD2 inhibitory activity) counseling platforms documenting dietary adherence must be available to detect inadvertent re-exposure explaining biochemical or blood pressure relapse. Monitor dietary counseling and exposure tracking platforms at 1-minute intervals during clinical hours.
What to Monitor on an Apparent Mineralocorticoid Excess Care Tech Platform
24-Hour Urine Steroid Profiling — The Diagnostic Core
Monitor 24-hour urine steroid GC-MS records (gas chromatography-mass spectrometry urinary steroid profiling — the comprehensive urine steroid analysis generating a full steroid metabolite profile from a timed 24-hour urine collection: tetrahydrocortisol [THF — the 3α,5β-reduced metabolite of cortisol], allotetrahydrocortisol [alloTHF — the 3α,5α-reduced metabolite of cortisol], and tetrahydrocortisone [THE — the 3α,5β-reduced metabolite of cortisone]; the THF+alloTHF/THE ratio calculated from these three metabolites — diagnostic threshold >3 for AME in adults [some laboratories use >4 or specific Z-score thresholds]; the degree of ratio elevation correlating with the severity of the 11β-HSD2 enzyme deficiency from the biallelic HSD11B2 mutation severity; serial 24-hour urine GC-MS during dexamethasone therapy to monitor for cortisol metabolite reduction confirming ACTH suppression and for cortisone metabolite changes reflecting partial 11β-HSD2 activity restoration in cases of compound heterozygous mutations with one mild allele), plasma cortisol-to-cortisone ratio records (plasma free cortisol and cortisone by LC-MS/MS — a more rapidly available screening measurement when 24-hour urine GC-MS is not immediately accessible; normally the cortisone-to-cortisol molar ratio is approximately 1:1 in plasma; elevated plasma cortisol/cortisone ratio [>1.5 to 2] suggests impaired peripheral cortisol-to-cortisone conversion consistent with 11β-HSD2 deficiency; serial plasma cortisol/cortisone ratio monitoring during dexamethasone titration), 24-hour urine free cortisol records (urine free cortisol by LC-MS/MS or competitive immunoassay — total 24-hour cortisol production; baseline documentation and monitoring during dexamethasone therapy to confirm ACTH and cortisol production suppression; suppression target typically <50 nmol/24h), plasma ACTH records (ACTH by IRMA — confirms dexamethasone-induced ACTH suppression; target near-zero ACTH during dexamethasone therapy confirming adequate pituitary suppression and consequent adrenal cortisol production reduction), and plasma cortisol and cortisone response to dexamethasone records (dexamethasone suppression test data — basal and post-dexamethasone cortisol documenting the degree of glucocorticoid-axis suppression achievable with the current dexamethasone dose) — at a 1-minute interval during laboratory hours. Alert immediately — 24-hour urine GC-MS platform failures during the biochemical evaluation of a hypertensive patient with hypokalemia and suppressed aldosterone delay the THF+alloTHF/THE ratio result that distinguishes AME (elevated ratio — treat with spironolactone and dexamethasone) from Liddle syndrome (normal ratio — treat with amiloride) — a distinction that determines which of two entirely different therapeutic classes should be initiated and which would be ineffective or potentially harmful.
Plasma Renin-Aldosterone and Mineralocorticoid Excess Biochemistry
Monitor plasma renin activity records (PRA by radioimmunoassay — suppressed in AME [PRA <0.2 ng/mL/h typical] from volume expansion by cortisol-driven MR activation in distal nephron; off-medication measurement for diagnostic confirmation — same interference considerations as Liddle syndrome evaluation; serial renin monitoring during spironolactone and dexamethasone therapy — rising renin confirms MR blockade releasing the suppressed renin axis), plasma aldosterone records (PAC by LC-MS/MS — paradoxically suppressed in AME [typically <5–8 ng/dL] from renin suppression reducing angiotensin II and thereby reducing adrenal aldosterone secretion; the suppressed-aldosterone-suppressed-renin biochemical pattern shared with Liddle syndrome — the urine steroid profile distinguishes the two; rising aldosterone during MR blockade with spironolactone confirms release of the renin-angiotensin-aldosterone axis), aldosterone-to-renin ratio records (ARR — appropriately interpreted in AME context as distinguishing from primary hyperaldosteronism where ARR is elevated; in AME and Liddle syndrome ARR is low-to-normal from suppressed aldosterone and suppressed renin), adrenal CT imaging records (CT adrenals — bilateral adrenal size and morphology to exclude aldosterone-producing adenoma or bilateral adrenal hyperplasia that could alternatively explain suppressed-renin hypertension; normal adrenal morphology expected in AME; adrenal vein sampling considered when adrenal CT shows an adrenal nodule to exclude primary hyperaldosteronism from a lateralizing aldosterone-producing adenoma before attributing to HSD11B2 deficiency), and 24-hour urine sodium records (24-hour urine sodium — elevated reflecting ENaC-mediated sodium retention driven by cortisol-MR activation; monitoring reduction during MR blockade and dexamethasone therapy) — at a 1-minute interval during laboratory hours.
HSD11B2 Molecular Genetics
Monitor HSD11B2 sequencing records (sequencing of the HSD11B2 gene — 5 exons encoding the 405-amino-acid 11β-HSD2 enzyme; missense mutations at highly conserved substrate-binding or cofactor-binding residues including R213C, R337C, F215L, and other catalytic domain variants associated with complete or near-complete loss of 11β-HSD2 activity; common mutations by population — R213C and R337C prevalent in Western AME cohorts; ACMG variant classification; biallelic confirmation — both alleles carrying loss-of-function variants confirming autosomal recessive AME; compound heterozygotes with one severe and one milder allele exhibiting partial enzyme activity and milder biochemical phenotype), HSD11B2 enzyme activity records (11β-HSD2 enzyme activity assay in kidney cortex fibroblasts or renal biopsy material using [3H]-cortisol to cortisone conversion — confirmatory functional evidence for novel variants of uncertain significance; activity typically <5% of normal in severe AME; partial activity [5–30% of normal] in milder compound heterozygous cases), carrier cascade testing records (obligate heterozygous parents confirmed by sequencing; at-risk sibling testing for biallelic variants; 25% per-pregnancy recurrence risk for couples with two carrier parents; autosomal recessive pedigree counseling), prenatal diagnosis records (chorionic villus sampling or amniocentesis for biallelic HSD11B2 variants in at-risk pregnancies; amniotic fluid cortisol-to-cortisone ratio as supportive biochemical prenatal evidence), and genetic counseling records (autosomal recessive inheritance; cascade family testing; reproductive planning; severity prediction from compound heterozygous genotype when one milder allele is present) — at a 1-minute interval during laboratory hours. Alert on failures — HSD11B2 sequencing platform failures delay the genetic confirmation distinguishing genetic AME (biallelic HSD11B2 mutations — lifelong condition requiring ongoing spironolactone and dexamethasone management) from acquired glycyrrhizin-induced AME (no HSD11B2 mutations — condition fully reversible with licorice and tobacco avoidance, no pharmacotherapy required), a distinction that prevents the unnecessary lifelong prescription of spironolactone and dexamethasone (with associated risk of adrenal insufficiency from HPA axis suppression) in acquired AME patients who simply need dietary counseling.
Ambulatory Blood Pressure Monitoring
Monitor 24-hour ABPM records (24-hour ABPM as the primary hypertension severity and treatment response documentation tool in AME — where blood pressure is typically among the most severe in endocrine hypertension, often exceeding 180/110 mmHg at diagnosis with high early-morning surge and non-dipping pattern from cortisol-driven MR activation throughout the aldosterone-equivalent diurnal pattern; pre-treatment ABPM establishing the severity baseline; serial ABPM at 6–12 weeks after spironolactone initiation documenting initial MR blockade BP response; serial ABPM at 6–12 weeks after adding dexamethasone documenting combined MR blockade and cortisol suppression effect; target blood pressure <130/80 mmHg daytime average; quarterly ABPM during stable combination therapy), home blood pressure records (daily morning and evening home BP logs during treatment titration phase — real-time titration data between clinic visits; app-based transmission for clinician review), and pediatric blood pressure normative records (age-height adjusted blood pressure percentiles for childhood AME presentation — some of the most severe pediatric hypertension encountered in metabolic medicine) — at a 1-minute interval during clinical hours.
Spironolactone and Dexamethasone Pharmacotherapy Monitoring
Monitor spironolactone therapy records (spironolactone dosing logs — starting dose [25–50 mg/day]; titration to 100–400 mg/day as needed for blood pressure and potassium normalization; mechanism: competitive MR antagonist blocking cortisol binding to MR in 11β-HSD2-deficient tissues; side effect monitoring — gynecomastia, menstrual irregularities, hyperkalemia from excessive MR blockade [more likely at high doses]; potassium monitoring at weekly intervals during uptitration; alternative eplerenone [more selective MR antagonist without antiandrogen side effects] when spironolactone side effects limit titration), dexamethasone therapy records (dexamethasone dosing logs — low-dose dexamethasone [0.25–0.5 mg/day or 0.5–1 mg every other day] given at bedtime to suppress the nocturnal ACTH pulse and thereby reduce morning cortisol production, reducing cortisol substrate available to activate MR in 11β-HSD2-deficient tissues; 24-hour urine free cortisol monitoring to confirm ACTH/cortisol suppression without excessive suppression; morning plasma cortisol confirmation of adequate suppression; risk of iatrogenic glucocorticoid excess — Cushing features, adrenal suppression, metabolic effects — from over-treatment requiring clinical and biochemical monitoring at each dexamethasone dose adjustment; stress-dose steroid protocol planning for intercurrent illness when dexamethasone is in use), dietary counseling and licorice avoidance records (complete licorice dietary history at diagnosis; glycyrrhizin source identification — confectionery, herbal teas [licorice root], anise-flavored tobacco, herbal supplements, mouthwash, some pharmaceutical excipients; licorice avoidance counseling documentation; tobacco product avoidance counseling — tobacco containing glycyrrhizin-related 11β-HSD2 inhibitors; dietary adherence confirmation at follow-up visits; re-exposure inquiry when biochemical relapse occurs), and potassium supplementation records (oral potassium supplementation during pre-spironolactone hypokalemia period; IV potassium for severe hypokalemia with ECG changes; supplementation cessation monitoring when spironolactone MR blockade corrects potassium without ongoing supplementation) — at a 1-minute interval during clinical hours.
Serum Electrolyte and Metabolic Monitoring
Monitor serum potassium records (serum potassium — hypokalemia [often <3.0 mEq/L at AME diagnosis, sometimes <2.5 mEq/L] from cortisol-MR-driven ROMK and BK channel potassium secretion in the distal nephron; critical potassium threshold <3.0 mEq/L triggering urgent ECG and arrhythmia risk assessment; serial monitoring weekly during spironolactone uptitration — potassium rising as MR blockade reduces cortisol-driven potassium wasting; target potassium 3.5–5.0 mEq/L; hyperkalemia monitoring >5.5 mEq/L at high spironolactone doses), serum sodium records (serum sodium — typically normal in AME despite ENaC-driven sodium retention, from compensatory water retention; sodium monitoring during dexamethasone therapy and high-dose spironolactone), serum bicarbonate records (metabolic alkalosis from concurrent H+ secretion driven by cortisol-MR activation of intercalated cell H+-ATPase; bicarbonate normalization during MR blockade and cortisol suppression), serum creatinine and eGFR records (baseline renal function; monitoring for hypertensive nephropathy from the prolonged severe hypertension of undiagnosed or inadequately treated AME; serial eGFR during treatment), and 24-hour urine electrolyte records (24-hour urine sodium and potassium confirming the biochemical response to MR blockade — rising urine sodium and falling urine potassium with effective spironolactone treatment) — at a 1-minute interval during laboratory hours.
Cardiac Monitoring — ECG and Echocardiography
Monitor ECG records (12-lead ECG — hypokalemia-driven T wave flattening, U waves, ST-segment changes, and QTc prolongation in untreated AME with severe hypokalemia; QTc monitoring threshold >460 ms triggering urgent potassium correction; LVH voltage criteria; rhythm surveillance for ventricular arrhythmia risk from combined hypokalemia and hypertensive LVH; serial ECG during spironolactone uptitration confirming QTc normalization), echocardiography records (LV wall thickness — IVSd and PWd measurement; LV mass index for LVH severity; LV geometry and diastolic function assessment; comparison with prior echo documenting LVH regression during sustained BP control — the primary long-term cardiac endpoint), and end-organ damage records (carotid intima-media thickness for vascular aging assessment; coronary artery calcium scoring in AME adults with prolonged history of severe hypertension; cerebrovascular MRI in patients with neurological symptoms from hypertensive small vessel disease) — at a 1-minute interval during clinical hours.
Authentication and Clinical Identity
Monitor authentication at 1-minute intervals, 24/7. AME management coordinates across endocrine hypertension medicine (steroid profiling and renin-aldosterone biochemistry), clinical biochemistry (GC-MS urine steroid profiling), molecular genetics (HSD11B2 sequencing), nephrology (renal function and spironolactone management), endocrinology (dexamethasone cortisol suppression and HPA axis monitoring), cardiology (LVH regression echocardiography and ECG surveillance), nutrition and dietary medicine (licorice and tobacco avoidance counseling), and genetic counseling (autosomal recessive cascade testing and reproductive planning) — authentication failures block every team member required to execute the biochemical steroid profiling, pharmacotherapy titration, and end-organ damage surveillance that define comprehensive AME care.
SSL Certificates
Monitor SSL certificate expiry across all 24-hour urine steroid profiling platforms, plasma cortisol-to-cortisone ratio systems, HSD11B2 sequencing portals, ABPM interpretation platforms, echocardiography systems, and dietary counseling portals. Certificate errors simultaneously disrupt communication between the biochemistry laboratory, molecular genetics team, endocrine hypertension clinician, and cardiac surveillance team required to integrate the steroid profiling results, genetic confirmation, blood pressure response, and end-organ damage assessment that together define AME management decisions.
HIPAA and Ultra-Rare Genetic Disease Patient Privacy Considerations
Apparent mineralocorticoid excess technology platforms handle highly sensitive PHI for a patient population with genetic HSD11B2 deficiency prevalence below 1 in 1,000,000 — one of the rarest conditions in endocrine medicine. Records include HSD11B2 biallelic molecular testing (heritable autosomal recessive mutations with implications for parent carrier status, sibling risk, and reproductive planning), 24-hour urine steroid profiling results documenting the cortisol-to-cortisone metabolism defect that constitutes the biochemical diagnosis, serial blood pressure and electrolyte records documenting disease severity and treatment response, dexamethasone therapy records (with the attendant adrenal suppression risk that makes dexamethasone dosing records particularly sensitive), and dietary counseling records including tobacco use history.
The genetic nature of HSD11B2 mutations creates obligations under GINA for employment and insurance discrimination protection. For platforms performing 24-hour urine GC-MS steroid profiling — whose results directly determine whether spironolactone or amiloride is the correct treatment — HIPAA Security Rule requirements for result transmission encryption and access auditing apply, and platform availability monitoring demonstrates the operational reliability standard required for decisions with directly different treatment implications.
Alerting Strategy for AME Tech Platforms
Immediate laboratory-hours alerting for 24-hour urine GC-MS steroid profiling platforms: The THF+alloTHF/THE ratio cannot fail during the diagnostic evaluation of suppressed-renin-suppressed-aldosterone hypertension — its result directly determines whether spironolactone or amiloride is the appropriate therapy.
Immediate laboratory-hours alerting for plasma cortisol-to-cortisone ratio platforms: Screening plasma cortisol/cortisone ratio and 24-hour urine free cortisol platforms during dexamethasone titration must remain available.
Immediate laboratory-hours alerting for HSD11B2 molecular genetics platforms: Genetic confirmation distinguishing genetic from acquired AME, enabling cascade testing and prenatal diagnosis.
Immediate laboratory-hours alerting for renin-aldosterone platforms: PRA and PAC confirming the suppressed-aldosterone-suppressed-renin pattern and monitoring treatment response.
Immediate laboratory-hours alerting for serum electrolyte platforms: Potassium monitoring during spironolactone uptitration — hypokalemia correction is the primary electrolyte efficacy endpoint.
Immediate clinical-hours alerting for ABPM and blood pressure monitoring: Blood pressure treatment response tracking during dual spironolactone and dexamethasone titration.
Immediate clinical-hours alerting for cardiac surveillance platforms: ECG for QTc and LVH, echocardiography for LVH regression monitoring.
Sustained-failure alert (10–15 minutes): Dietary counseling and licorice avoidance adherence tracking, genetic counseling cascade platforms, and stable AME patient routine monitoring.
30-day advance warning: SSL certificates across all domains.
Vigilmon's multi-region monitoring confirms AME platform availability from the geographies where endocrine hypertension specialist centers, clinical biochemistry laboratories with GC-MS steroid profiling capability, and rare genetic hypertension programs serve AME patients.
Status Page for AME Care Team Communication
A real-time status page gives endocrine hypertension physicians interpreting GC-MS urine steroid profiles, clinical biochemists generating THF+alloTHF/THE ratios, molecular geneticists sequencing HSD11B2, nephrologists managing spironolactone dose titration, endocrinologists monitoring dexamethasone cortisol suppression, cardiologists tracking LVH regression, dietary counselors reinforcing licorice avoidance, and genetic counselors coordinating autosomal recessive family cascade testing immediate platform visibility without requiring inbound IT support contact.
Include the status page URL in AME laboratory backup procedures, steroid profiling emergency protocols, and the endocrine hypertension clinic shared communication platforms where spironolactone and dexamethasone titration decisions are coordinated.
Vigilmon Setup for AME Tech Platforms
A practical starting configuration:
| Monitor | Check Interval | Alert Channel | |---------|----------------|---------------| | Authentication | 1 min | Slack + PagerDuty (24/7) | | 24-hour urine GC-MS steroid profile (THF, alloTHF, THE ratio) | 1 min | Slack + PagerDuty (lab hours) | | Plasma cortisol-to-cortisone ratio (LC-MS/MS) | 1 min | Slack + PagerDuty (lab hours) | | 24-hour urine free cortisol (dexamethasone suppression monitoring) | 1 min | Slack + PagerDuty (lab hours) | | Plasma ACTH (dexamethasone HPA suppression) | 1 min | Slack + PagerDuty (lab hours) | | Plasma renin activity (suppressed axis confirmation) | 1 min | Slack + PagerDuty (lab hours) | | Plasma aldosterone (suppressed — cortisol-mediated MR activation) | 1 min | Slack + PagerDuty (lab hours) | | Serum potassium (hypokalemia monitoring) | 1 min | Slack + PagerDuty (lab hours) | | Serum bicarbonate (metabolic alkalosis) | 1 min | Slack + PagerDuty (lab hours) | | Serum creatinine and eGFR | 1 min | Slack + PagerDuty (lab hours) | | 24-hour urine electrolytes (sodium/potassium ratio during MR blockade) | 1 min | Slack + PagerDuty (lab hours) | | HSD11B2 sequencing (biallelic loss-of-function) | 1 min | Slack + PagerDuty (lab hours) | | HSD11B2 enzyme activity assay (confirmatory) | 1 min | Slack + PagerDuty (lab hours) | | Carrier cascade testing (parents and siblings) | 1 min | Slack + PagerDuty (lab hours) | | 24-hour ABPM (hypertension severity and treatment response) | 1 min | Slack + PagerDuty (clinical hours) | | Home blood pressure log platform | 1 min | Slack + PagerDuty (clinical hours) | | Spironolactone adherence and dose titration logs | 1 min | Slack + PagerDuty (clinical hours) | | Dexamethasone therapy logs (dose, cortisol response) | 1 min | Slack + PagerDuty (clinical hours) | | ECG (QTc monitoring, LVH, arrhythmia surveillance) | 1 min | Slack + PagerDuty (clinical hours) | | Echocardiography (LVH regression, diastolic function) | 1 min | Slack + PagerDuty (clinical hours) | | Dietary counseling (licorice and tobacco avoidance) | 2 min | Slack (clinical hours) | | Adrenal CT imaging (adenoma exclusion) | 2 min | Slack (clinical hours) | | Genetic counseling and prenatal diagnosis coordination | 2 min | Slack (business hours) | | SSL: all domains | Daily | Email (30-day warning) |
Getting started:
- Create a free account at vigilmon.online
- Add authentication endpoints at 1-minute intervals with 24/7 alerting
- Configure 24-hour urine GC-MS steroid profiling platforms with immediate laboratory-hours alerting — the primary diagnostic tool
- Add plasma cortisol-to-cortisone ratio platforms with immediate laboratory-hours alerting
- Configure 24-hour urine free cortisol platforms with immediate laboratory-hours alerting (dexamethasone monitoring)
- Add plasma ACTH platforms with immediate laboratory-hours alerting
- Configure plasma renin activity and aldosterone platforms with immediate laboratory-hours alerting
- Add serum potassium and bicarbonate platforms with immediate laboratory-hours alerting
- Configure HSD11B2 sequencing platforms with immediate laboratory-hours alerting
- Add HSD11B2 enzyme activity platforms with immediate laboratory-hours alerting
- Configure family cascade testing platforms with immediate laboratory-hours alerting
- Add 24-hour ABPM platforms with immediate clinical-hours alerting
- Configure home blood pressure log platforms with immediate clinical-hours alerting
- Add spironolactone adherence and titration platforms with immediate clinical-hours alerting
- Configure dexamethasone therapy and cortisol suppression monitoring platforms with immediate clinical-hours alerting
- Add ECG platforms with immediate clinical-hours alerting
- Configure echocardiography platforms with immediate clinical-hours alerting
- Add dietary counseling and licorice avoidance tracking with sustained-failure alerting
- Configure adrenal CT imaging platforms with sustained-failure alerting
- Add genetic counseling and prenatal diagnosis platforms with sustained-failure alerting during business hours
- Enable SSL certificate monitoring across all biochemistry, molecular genetics, blood pressure, and cardiac surveillance platforms
- Add the status page URL to AME laboratory backup procedures and endocrine hypertension clinic communication channels
Conclusion
Apparent mineralocorticoid excess technology platforms are embedded in clinical decisions where 24-hour urine GC-MS steroid profiling platform availability during the biochemical evaluation of a 16-year-old with blood pressure of 190/115 mmHg, serum potassium of 2.6 mEq/L, and suppressed plasma renin and aldosterone — when the endocrine hypertension consultant suspects either Liddle syndrome or AME based on the suppressed-aldosterone-suppressed-renin pattern and orders a 24-hour urine steroid profile to measure the THF+alloTHF/THE ratio that will determine which condition is present — cannot be disrupted by GC-MS steroid profiling platform failures that delay the ratio result while the adolescent remains on an ineffective drug (spironolactone has been empirically started and is providing no benefit if this is Liddle syndrome, or amiloride is being considered and would be suboptimally effective if this is AME requiring MR blockade specifically) and the clinical team cannot determine whether to continue, switch, or add the correct molecular-target-specific agent; where HSD11B2 sequencing platform availability during the genetic evaluation of the same adolescent — whose urine cortisol-to-cortisone ratio has returned markedly elevated (THF+alloTHF/THE = 28, versus normal 1–2), confirming the 11β-HSD2 deficiency biochemical phenotype, but where the molecular geneticist needs HSD11B2 sequencing to confirm biallelic mutations (establishing lifelong genetic AME requiring indefinite spironolactone and dexamethasone management with ongoing HPA axis monitoring) versus the absence of HSD11B2 mutations (establishing acquired glycyrrhizin-induced AME from the patient's habit of consuming licorice supplements for digestive health, in which case the entire pharmacotherapy regimen is unnecessary and simple licorice cessation will fully resolve the AME phenotype within weeks) — cannot be disrupted by HSD11B2 sequencing platform failures that leave this critical distinction unresolved and the clinician unable to determine whether to prescribe lifelong dexamethasone (with its attendant adrenal suppression, metabolic, and bone density risks) or simply counsel avoidance of a dietary supplement; and where dexamethasone cortisol suppression monitoring platform availability during the monthly follow-up of a patient on established genetic AME pharmacotherapy — when the endocrinologist is reviewing the 24-hour urine free cortisol to confirm that the bedtime dexamethasone 0.25 mg is adequately suppressing nocturnal ACTH and reducing morning cortisol production without producing the Cushingoid features, adrenal suppression, and metabolic adverse effects that over-suppression would cause — cannot be disrupted by urine cortisol platform failures that leave the clinician managing a patient on chronic exogenous glucocorticoid therapy without the biochemical monitoring data required to stay within the therapeutic window between inadequate cortisol suppression (AME inadequately treated) and excessive suppression (iatrogenic glucocorticoid excess). A 24-hour urine GC-MS steroid profiling platform unavailable when the THF+alloTHF/THE ratio is the sole test that differentiates AME from Liddle syndrome and determines which therapeutic class is effective, an HSD11B2 sequencing platform interrupted when the genetic confirmation result is the only way to distinguish lifelong genetic AME from fully reversible acquired glycyrrhizin-induced AME, a dexamethasone cortisol suppression monitoring platform unavailable when chronic low-dose glucocorticoid therapy requires biochemical HPA axis monitoring to prevent adrenal suppression — these are not IT incidents. They are clinical disruptions in the management of one of the rarest and most biochemically nuanced monogenic hypertension syndromes, where the distinction between a mutation in a cortisol-metabolizing enzyme (AME) and a mutation in the sodium channel the resulting cortisol-MR activation stimulates (Liddle syndrome) cannot be made by clinical examination alone, and where the steroid profiling biochemistry that makes this distinction must be available for the diagnostic evaluation to proceed, the therapeutic choice to be correctly made, and the long-term pharmacotherapy to be safely monitored.
Uptime monitoring gives AME tech teams the detection capability to identify failures within seconds, trigger immediate clinical downtime procedures, and demonstrate to endocrine hypertension centers, clinical biochemistry laboratories, molecular genetics services, and compliance auditors that platform operational reliability matches the GC-MS steroid profiling precision, genetic confirmation urgency, dual pharmacotherapy monitoring complexity, and end-organ damage surveillance obligations of modern AME care.
Start monitoring your apparent mineralocorticoid excess care tech platform for free at vigilmon.online — HTTP/HTTPS monitoring, multi-region consensus alerting, SSL certificate monitoring, automatic status page, Slack and webhook alerts. No agent required. No credit card.
Tags: #monitoring #apparent #mineralocorticoid #excess #AME #HSD11B2 #11beta-HSD2 #cortisol #cortisone #spironolactone #dexamethasone #licorice #glycyrrhizin #monogenic #hypertension #hypokalemia #renin #aldosterone #mineralocorticoid #receptor #rare #genetic #endocrine #nephrology #HIPAA #healthtech #digitalhealth #uptime #sre